Rosuvastatin pre-treatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis. The ROMA trial
Catheterization and Cardiovascular Interventions, 04/30/2012Sardella G et al.
High loading dose of Rosuvastatin within 24 hours before elective percutaneous coronary intervention (PCI) seems to decrease the incidence of periprocedural myocardial necrosis during a period of 12–months compared to the standard treatment.
160 patients with stable angina who underwent elective PCI were randomly assigned to receive either a pre–procedural loading dose (40 mg) of Rosuvastatin (RG n=80) or a standard treatment (CG n=80).
The primary end–point was the incidence of periprocedural myocardial necrosis.
The secondary end–point was the assessment of MACCE (cardiac death, all–MI,stroke and TVR) at a 30–day and 12–month follow–up, as well as the rate of periprocedural rise of Troponin T serum levels> 3xULN.
Twelve and 24–hour post–PCI CK–MB elevation>3x occurred more frequently in the CG than in the RG (22.7 vs 7.1;p=0.034 and 26.4 vs 8.7;p=0.003).
At the 30–day and 12–month follow–up the incidence of cumulative MACCEwas higher in CG than in the RG (30.0% vs 8.7%; p=0.001 and 35.0% vs 12.5%;p=0.001).
The difference between the groups was mainly due to the periprocedural MI incidence (26.4% vs 8.7%;p=0.003).
The rate of cardiac death, spontaneous MI, TVR and stroke were similar in the two groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.